LOGIN  |  REGISTER
Cue Biopharma
Assertio

Brookdale Senior Living Reports August 2025 Occupancy

September 09, 2025 | Last Trade: US$7.45 0.20 -2.61

NASHVILLE, Tenn., Sept. 9, 2025 /PRNewswire/ --Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for August 2025.

August 2025 Observations:

  • August consolidated weighted average occupancy grew 290 basis points year-over-year and 70 basis points sequentially to 81.8%.
  • Third quarter-to-date consolidated weighted average occupancy of 81.5% represents a 140 basis point sequential occupancy increase from the full second quarter.
  • August consolidated month end occupancy increased 60 basis points sequentially from July and 280 basis points compared to the prior year period.
  • August same community weighted average occupancy grew 260 basis points year-over-year to 82.2%.

Brookdale Reports August 2025 Occupancy.

About Brookdale Senior Living

Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. With 645 communities across 41 states and the ability to serve approximately 58,000 residents as of June 30, 2025, Brookdale is committed to its mission of enriching the lives of seniors through compassionate care, clinical expertise, and exceptional service. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities, offering tailored solutions that help empower seniors to live with dignity, connection, and purpose. Leveraging deep expertise in healthcare, hospitality, and real estate, Brookdale creates opportunities for wellness, personal growth, and meaningful relationships in settings that feel like home. Guided by its four cornerstones of passion, courage, partnership, and trust, Brookdale is committed to delivering exceptional value and redefining senior living for a brighter, healthier future. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.

 
Viking Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page